Sequana Medical NVFRA:2SE 31 Net Debt Paydown Yield % is -43.61% as of Jul. 12, 2026. GuruFocus rates FRA:2SE with a GF Score™ of 31/100 and a GF Value™ of €0.19. The stock has 12 warning signs investors should review. Among 773 Medical Devices & Instruments companies, Sequana Medical NV ranks worse than 96.77% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Sequana Medical NV's Net Debt Paydown Yield % was -43.61%.
Sequana Medical NV (FRA:2SE) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Sequana Medical NV Net Debt Paydown Yield % Related Terms
Sequana Medical NV Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Sequana Medical NV's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2SE vs ABT, SYK, MDT: Net Debt Paydown Yield % Comparison
For the Medical Devices subindustry, Sequana Medical NV's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sequana Medical NV Net Debt Paydown Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sequana Medical NV's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Sequana Medical NV's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of -43.61% mean?
Sequana Medical NV (FRA:2SE) has a Net Debt Paydown Yield % of -43.61% as of Jul. 12, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Sequana Medical NV and its competitors. According to the industry distribution chart, Sequana Medical NV ranks #748 out of 773 companies in the Medical Devices & Instruments industry, placing it in the top 96.8%.
Is Sequana Medical NV's Net Debt Paydown Yield % too high?
Sequana Medical NV's current Net Debt Paydown Yield % is -43.61%. Based on the distribution chart, Sequana Medical NV ranks #748 out of 773 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sequana Medical NV has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Sequana Medical NV's Net Debt Paydown Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sequana Medical NV ranks #748 out of 773 companies for Net Debt Paydown Yield %. This places Sequana Medical NV in the lower half of its industry. The industry median Net Debt Paydown Yield % is 0.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Medical Devices & Instruments company?
The median Net Debt Paydown Yield % among Medical Devices & Instruments companies is 0.01, based on 773 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Sequana Medical NV and its competitors. For the Medical Devices & Instruments industry, the median Net Debt Paydown Yield % is 0.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sequana Medical NV's current Net Debt Paydown Yield % is -43.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sequana Medical NV stock overvalued right now?
Sequana Medical NV (FRA:2SE) has a current Net Debt Paydown Yield % of -43.61%. The stock's GF Value™ is €0.19, compared to a current price of €0.51 — trading 169.5% above its estimated fair value. The current Net Debt Paydown Yield % is -43.61%. Sequana Medical NV's overall GF Score™ is 31/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Sequana Medical NV (FRA:2SE), the current Net Debt Paydown Yield % is -43.61% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sequana Medical NV (FRA:2SE) Overvalued in 2026?
Based on GuruFocus' analysis, Sequana Medical NV stock appears to be overvalued.
The current stock price of €0.51 is trading 169.5% above its estimated GF Value™ of €0.19.
Key valuation signals for FRA:2SE:
Net Debt Paydown Yield %: -43.61%
GF Value™: €0.19 vs. price of €0.51 (169.5% above fair value)
No single metric tells the full story. See the FRA:2SE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies. The company's geographical segments include Switzerland, Germany, the United Kingdom, France, and the Rest of the world, out of which Germany accounts for the majority of the revenue.
31GF Score
Get the complete analysis for FRA:2SE
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2SE has been successfully added to your 
